Adolescents’ Experiences Using the Contraceptive Patch versus Pills

Sucato, Gina S.; Land, Stephanie R.; Murray, Pamela J.; Cecchini, Reena S.; Gold, Melanie A.

doi:10.1016/j.jpag.2011.02.001

Cited by 22 publications

(8 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…177 Even lower rates of patch continuation, ranging from 25% to 50%, have been found in other longitudinal studies of adolescent patch users. [179][180][181] In addition, similar findings have been shown in randomized studies of adults. A 2010 Cochrane review 182 (based on 4 such studies) concluded that patch users were more likely than pill users to discontinue study participation because of adverse effects.…”

Section: Pediatrics Volume 134 Number 4 October 2014 E1267supporting

confidence: 79%

“…[177][178][179] For example, Bakhru and Stanwood 177 prospectively followed 1230 women (416 of whom were 17 years or younger) who self-selected their method and found 57% continuation of the patch at 1 year compared with 76% continuation of the pill (P = .004). In contrast to their initial hypothesis, patch users were significantly less likely than pill users to continue their method and, thus, were more likely to experience pregnancy.…”

Section: Pediatrics Volume 134 Number 4 October 2014 E1267mentioning

confidence: 99%

See 1 more Smart Citation

Contraception for Adolescents

Ott

Sucato²

2014

Pediatrics

Self Cite

245

133

View full text Add to dashboard Cite

A working knowledge of contraception will assist the pediatrician in both sexual health promotion as well as treatment of common adolescent gynecologic problems. Best practices in adolescent anticipatory guidance and screening include a sexual health history, screening for pregnancy and sexually transmitted infections, counseling, and if indicated, providing access to contraceptives. Pediatricians’ long-term relationships with adolescents and families allow them to help promote healthy sexual decision-making, including abstinence and contraceptive use. Additionally, medical indications for contraception, such as acne, dysmenorrhea, and heavy menstrual bleeding, are frequently uncovered during adolescent visits. This technical report provides an evidence base for the accompanying policy statement and addresses key aspects of adolescent contraceptive use, including the following: (1) sexual history taking, confidentiality, and counseling; (2) adolescent data on the use and side effects of newer contraceptive methods; (3) new data on older contraceptive methods; and (4) evidence supporting the use of contraceptives in adolescent patients with complex medical conditions.

show abstract

Section: Pediatrics Volume 134 Number 4 October 2014 E1267supporting

confidence: 79%

Section: Pediatrics Volume 134 Number 4 October 2014 E1267mentioning

confidence: 99%

Contraception for Adolescents

Ott

Sucato²

2014

Pediatrics

Self Cite

245

133

View full text Add to dashboard Cite

show abstract

“…The type of progestogen [Lawrie et al 2011; Maitra et al 2004] and the number of oral contraceptive pill packages dispensed [Foster et al 2006], prescription drug or over-the-counter [Potter et al 2011] have all been proposed as determinants for continuation. Improvements of formulations of combined hormonal contraception, including new routes of administration and different regimens, that is, monophasic, biphasic, triphasic and quadriphasic pills, patches and vaginal rings, have been performed in order to increase compliance and continuation [Sucato et al 2011; Murphy and Brixner, 2008], but, so far, there is only limited evidence that use of a specific formulation or route of administration would be a better choice concerning continuation rates.…”

Section: Compliance/continuation Ratesmentioning

confidence: 99%

Combined hormonal contraceptives: prescribing patterns, compliance, and benefits versus risks

Brynhildsen

2014

Therapeutic Advances in Drug Safety

127

View full text Add to dashboard Cite

Combined hormonal contraceptives [combined oral contraceptives (COCs)] have been available for over 50 years and the impact of this invention may not be overestimated. Today over 100 million women are current users and in Western Europe and the United States approximately 80% of women of fertile ages can be considered as ever-users. Over the years several drawbacks have been identified and media alarms on risks are frequently presented, resulting in suboptimal compliance and low compliance and continuation rates. Poor compliance and discontinuation is a big problem and is not generally identified by prescribers. During ideal use COCs offer very good protection against unwanted pregnancies, however there is a big problem with compliance and continuation and thus the 'real-life' efficacy is much lower. Reasons for poor compliance include side effects and fear of side effects and it is crucial that the prescriber gives the individual woman thorough and balanced information on the benefits and risks. Most well known is the increased risk of venous thromboembolism, but also an elevated risk of arterial thrombosis and several types of cancer has been reported. The risk estimates are low but according to the large number of users a substantial number of extra cases will occur. However, use of COCs also offers several additional health benefits with significant impact on morbidity and quality of life. COC use is associated with a substantial decrease in the risk of ovarian cancer, endometrial cancer and colorectal cancer. Moreover, COCs are a major option of treatment for women suffering from heavy menstrual bleeding and dysmenorrhea as well as hirsutism and acne vulgaris. The net effect of the additional health effects of COC-use may very well be positive, i.e. a slight increase in life expectancy.

show abstract

“…Moreover, improvements of the formulations of combined hormonal contraceptives (COC) have been made in order to increase continuation rates. Such improvements include new routes of administration and different regimens, that is, monophasic, biphasic, triphasic and quadriphasic pills, patches and vaginal rings 8 9. So far, there is only limited evidence that use of a specific formulation or route of administration would be a better choice concerning continuation rates 4–9…”

Section: Introductionmentioning

confidence: 99%

Continuation rates of oral hormonal contraceptives in a cohort of first-time users: a population-based registry study, Sweden 2005–2010

et al. 2013

View full text Add to dashboard Cite

ObjectiveTo investigate if continuation rates in first-time users of oral hormonal contraceptives differed between different formulations and to measure if the rates were related to the prescribing categories, that is, physicians and midwives.DesignA longitudinal national population-based registry study.SettingThe Swedish prescribed drug register.ParticipantsAll women born between 1977 and 1994 defined as first-time users of hormonal contraceptives from 2007 to 2009 (n=226 211).Main outcome measuresA tendency to switch the type of hormonal contraceptive within 6 months use and repeated dispensation identical to the first were estimated as percentages and relative risks (RRs). Physicians’ and midwives’ prescription patterns concerning the women's continuation rates of oral hormonal contraceptive type.ResultsIn Sweden, there were 782 375 women born between 1977 and 1994 at the time of the study. Of these, 226 211 women were identified as first-time users of hormonal contraceptives. Ethinylestradiol+levonorgestrel, desogestrel-only and ethinylestradiol+drospirenone were the hormonal contraceptives most commonly dispensed to first-time users at rates of 43.3%, 24.4% and 11.1%, respectively. The overall rate of switching contraceptive types in the first 6 months was 11.3%, which was highest for desogestrel-only (14.3%) and lowest for ethinylestradiol+drospirenone (6.6%). The switching rate for all three products was highest in the 16-year to 19-year age group. Having a repeated dispensation identical to the initial dispensation was highest for users of ethinylestradiol either combined with levonorgestrel or drospirenone, 81.4% and 81.2%, respectively, whereas this rate for the initial desogestrel-only users was 71.5%. The RR of switching of contraceptive type within the first 6 months was 1.35 (95% CI 1.32 to 1.39) for desogestrel-only and 0.63 (0.59 to 0.66) for ethinylestradiol+drospirenone compared with ethinylestradiol+levonorgestrel as the reference category. There were no differences in the women's continuation rates depending on the prescriber categories.ConclusionsDesogestrel-only users conferred the highest switcher rate to another hormonal contraceptive within a 6-month period. Users of ethinylestradiol+levonorgestrel were more prone to switch to another product within 6 months than women using ethinylestradiol+drospirenone. These findings may be of clinical importance when tailoring hormonal contraceptives on an individual basis.

show abstract

Adolescents’ Experiences Using the Contraceptive Patch versus Pills

Cited by 22 publications

References 45 publications

Contraception for Adolescents

Contraception for Adolescents

Combined hormonal contraceptives: prescribing patterns, compliance, and benefits versus risks

Continuation rates of oral hormonal contraceptives in a cohort of first-time users: a population-based registry study, Sweden 2005–2010

Contact Info

Product

Resources

About